ARWR supply chain intelligence for Arrowhead Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Arrowhead Pharmaceuticals, Inc. (ARWR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RPRX | Royalty Pharma plc | 85% | In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the O… |
| RPRX | Royalty Pharma plc | 85% | Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from RPRX graph: Reciprocal relationship from ARWR graph: In consideration for the payment of… |
| VISIRNA-THERAPEUTICS-INC | VISIRNA-THERAPEUTICS-INC | 80% | On August 1, 2025, Visirna Therapeutics HK Limited (“Visirna HK”), a wholly owned subsidiary of Visirna Therapeutics, Inc, a majority owned subsidiary of the Company, entered into an Asset Purchase A… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from IBIO g… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: Reciprocal relationship from ARWR graph: rrowhead’s plozasiran product and the ’333 patent. 47. Arrowhead is entitled to a judicial declaration that the makin… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | rrowhead’s plozasiran product and the ’333 patent. 47. Arrowhead is entitled to a judicial declaration that the making, use, offer for sale, sale, or import into the United States of Arrowhead’s ploz… |
| PEPG | PepGen Inc. | 72% | Reciprocal relationship from PEPG graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from PEPG graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from PEPG g… |
| SRPT | Sarepta Therapeutics, Inc. | 72% | Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT g… |
| 180-DAYS-WRITTEN-NOTICE | 180-DAYS-WRITTEN-NOTICE | 70% | Collaboration Agreement with 180 days' written notice to the Company if terminated after any regulatory approval of a licensed product |
| 30-DAYS-WRITTEN-NOTICE | 30-DAYS-WRITTEN-NOTICE | 70% | Collaboration Agreement with 30 days' written notice to the Company if terminated prior to any regulatory approval of a licensed product |
| EVTL | Vertical Aerospace Ltd. | 62% | Reciprocal relationship from EVTL graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from EVTL graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from EVTL g… |
| GLOB | Globant S.A. | 62% | Reciprocal relationship from GLOB graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from GLOB graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from GLOB g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NVS | Novartis AG | 92% | Reciprocal relationship from NVS graph: Reciprocal relationship from ARWR graph: For the three months ended March 31, 2026, the Company recorded $ 20.5 million in revenue from Novartis. |
| NVS | Novartis AG | 92% | For the three months ended March 31, 2026, the Company recorded $ 20.5 million in revenue from Novartis. |
| SNYNF | Sanofi | 92% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SNYN… |
| SAREPTA | SAREPTA | 90% | During the six months ended March 31, 2026, the Company recorded $271.2 million in revenue. |
| SANOFI | SANOFI | 85% | partially offset by increased revenue from Novartis and Sanofi, reflecting the timing and progress of the Company’s respective collaboration and license agreements. |
| SNYNF | Sanofi | 85% | nded September 30, 2025. RESULTS OF OPERATIONS The following data summarizes the Company’s results of operations for the following periods indicated: Three Months Ended March 31, Six Months Ended Mar… |
| AMGN | Amgen Inc. | 80% | The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. |
| AMGN | Amgen Inc. | 80% | Reciprocal relationship from AMGN graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ARWR graph: The Company remains eligible to rec… |
| SRPT | Sarepta Therapeutics, Inc. | 80% | Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from SRPT g… |
| DYN | Dyne Therapeutics, Inc. | 72% | Reciprocal relationship from DYN graph: ces and our business and operations, including clinical trials, could be disrupted by any problems with our significant third-party vendors. We engage a number… |
| IBIO | iBio, Inc. | 72% | Reciprocal relationship from IBIO graph: Biohaven, Ltd., Structure Therapeutics, Inc., Viking Therapeutics, Inc., Veru Inc., Zealand Pharma A/S, Metsera, Inc., Terns Pharmaceuticals, Inc., Skye Biosc… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue … |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | rrowhead’s plozasiran product and the ’333 patent. 47. Arrowhead is entitled to a judicial declaration that the making, use, offer for sale, sale, or import into the United States of Arrowhead’s ploz… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from ARWR graph: Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $132.7 million and $101.9 million for the three and six… |
| NVSEF | Novartis AG | 72% | Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $132.7 million and $101.9 million for the three and six months ended March 31, 2026, compared to a net income attributable to Arrowhead Ph… |
| VKTX | Viking Therapeutics, Inc. | 72% | Reciprocal relationship from VKTX graph: y a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinica… |
| NOVARTIS-PHARMA-AG | NOVARTIS-PHARMA-AG | 62% | ettled in cash. The shares were recorded as treasury stock at their fair value of $ 53.2 million, resulting in a $ 3.2 million gain on settlement. The repurchased shares are presented as a reduction … |
| VISIRNA-THERAPEUTICS-HK-LIMITED | VISIRNA-THERAPEUTICS-HK-LIMITED | 62% | 285.0 million and $ 370.0 million per program as well as tiered royalties on net sales of licensed products of up to the low double digits, subject to the terms and conditions of the Novartis Collabo… |
| VISIRNA-THERAPEUTICS-INC | VISIRNA-THERAPEUTICS-INC | 62% | nded September 30, 2025. RESULTS OF OPERATIONS The following data summarizes the Company’s results of operations for the following periods indicated: Three Months Ended March 31, Six Months Ended Mar… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ARWR-DEBT | Debt stack $1.4B | 90% | Market cache reports total debt of $1.4B. |
| ARWR-DEBT-7864 | Warrants outstanding: 917441 | 90% | xbrl warrant detail from xbrl 2025-09-30. |
| ARWR-DEBT-58576 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ARWR-OWNER-BARCLAYS-PLC | BARCLAYS PLC | 95% | 13F/ownership overlay lists BARCLAYS PLC; shares held 3,731,426; value $105.8B; as of 2026-03-31. |
| ARWR-OWNER-BLACKROCK-INC | BlackRock, Inc. | 95% | 13F/ownership overlay lists BlackRock, Inc.; shares held 18,161,519; value $1.14T; as of 2026-03-31. |
| ARWR-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 95% | 13F/ownership overlay lists MORGAN STANLEY; shares held 4,139,186; value $216.9B; as of 2026-03-31. |
| ARWR-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 95% | 13F/ownership overlay lists Avoro Capital Advisors LLC; shares held 21,324,999; ownership 15.10%; value $1.38T; as of 2026-03-31. |
| ARWR-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD CAPITAL MANAGEMENT LLC; shares held 12,064,832; value $756.5B; as of 2026-03-31. |
| ARWR-OWNER-FMR-LLC | FMR LLC | 95% | 13F/ownership overlay lists FMR LLC; shares held 7,266,652; value $455.6B; as of 2026-03-31. |
| ARWR-OWNER-STATE-STREET-CORP | STATE STREET CORP | 95% | 13F/ownership overlay lists STATE STREET CORP; shares held 6,496,130; value $407.3B; as of 2026-03-31. |
| ARWR-OWNER-GOLDMAN-SACHS-GROUP-INC | GOLDMAN SACHS GROUP INC | 95% | 13F/ownership overlay lists GOLDMAN SACHS GROUP INC; shares held 3,437,445; value $221.8B; as of 2026-03-31. |
| ARWR-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | GEODE CAPITAL MANAGEMENT, LLC | 95% | 13F/ownership overlay lists GEODE CAPITAL MANAGEMENT, LLC; shares held 4,278,828; value $274.5B; as of 2026-03-31. |
| ARWR-OWNER-VANGUARD-PORTFOLIO-MANAGEMENT-LLC | VANGUARD PORTFOLIO MANAGEMENT LLC | 95% | 13F/ownership overlay lists VANGUARD PORTFOLIO MANAGEMENT LLC; shares held 7,146,136; value $448.1B; as of 2026-03-31. |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 82% | Hamilton James C | Chief Medical Officer | sell | 10000 shares |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 82% | Hamilton James C | Chief Medical Officer | sell | 10000 shares |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| AMGN | Amgen Inc. | 100.00 | 1 | ['customer'] |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| LGND | Ligand Pharmaceuticals Incorporated | 100.00 | 2 |